Abstract: The present specification discloses one or more anti-oncogenic phytochemicals comprising one or more compounds of chemical formula I: wherein R1is independently selected from H, CH3 or C2H5or is not present; R2 is independently selected from H, CH3 or C2H5 or is not present; provided that when R1 is not present, R2 is selected from H, CH3 or C2H5 and when R2 is not present R1 is selected from H, CH3 or C2H5: R3 is a C4-40 straight or branched chain, alkyl or alkylene and optionally substituted with one or more groups independently selected from CH3, OH, SH, NH2, OMe, OEt, N(H)Me and NMe2; and X is independently selected from CH3, OH, SH, NH2, OMe, OEt, N(H)Me, and NMe2, as well as, extracts, pharmaceutical compositions and medicaments comprising the one or more anti-oncogenic phytochemicals disclosed herein, methods of preparing such extracts, pharmaceutical compositions, and medicaments comprising the one or more anti-oncogenic phytochemicals , and methods and uses for treating a neoplasm or a cancer usi

Abstract: The present specification discloses one or more anti-oncogenic phytochemicals, extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals disclosed herein, methods of preparing extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals, extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals prepared according to methods disclosed herein, and methods and uses for treating a neoplasm or a cancer using one or more anti-oncogenic phytochemicals as well as extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals disclosed herein.

Abstract: Disclosed herein are conditional siRNAs activatable by CBF?-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Abstract: Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.

Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

Abstract: The present specification discloses one or more anti-oncogenic phytochemicals, extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals disclosed herein, methods of preparing extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals, extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals prepared according to methods disclosed herein, and methods and uses for treating a neoplasm or a cancer using one or more anti-oncogenic phytochemicals as well as extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals disclosed herein.

Abstract: The disclosure provides, inter alia, hybridized nucleic acid sequences and compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA passenger strand sequence hybridized to a microRNA guide strand sequence; pharmaceutical compositions comprising the hybridized nucleic acid sequences and compounds; and the use of the hybridized nucleic acid sequences, compounds, and pharmaceutical compositions to treat medical conditions, such as cancer and inflammatory diseases.

Abstract: Disclosed herein are conditional siRNAs activatable by CBF?-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.

Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

Abstract: Provided herein are, inter alia, Interleukin-1 receptor accessory protein (IL1RAP) antibodies and fragments thereof which may form part of chimeric antigen receptors or bispsecific antibodies and are useful for treating IL1RAP-expressing cancers.

Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.

Abstract: Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.

Abstract: Disclosed herein are conditional siRNAs activatable by CBF?-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

Abstract: Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.

Abstract: Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.

Abstract: Provided herein are boronic acid esters of boronic acid therapeutic agents, such as bortezomib. The boronic acid esters can be used to prepare liposomal formulations of boronic acid therapeutic agents with improved properties, such as enhanced stability. This disclosure, in one aspect, relates to compositions and methods of making and using the compositions.

Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.